Therapeutic options in treatment-resistant depression

被引:71
作者
Vieta, Eduard [1 ]
Colom, Francesc [1 ]
机构
[1] Univ Barcelona, Bipolar Disorders Program, Hosp Clin, IDIBAPS,CIBERSAM, E-08036 Barcelona, Catalonia, Spain
关键词
Depression; resistance; treatment; TRANSCRANIAL MAGNETIC STIMULATION; PLACEBO-CONTROLLED TRIAL; VAGUS NERVE-STIMULATION; SEROTONIN REUPTAKE INHIBITORS; DEEP BRAIN-STIMULATION; STAR-ASTERISK-D; D-ASPARTATE ANTAGONIST; NONPSYCHOTIC MAJOR DEPRESSION; ANXIETY TREATMENTS CANMAT; BIPOLAR-II DEPRESSION;
D O I
10.3109/07853890.2011.583675
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The phenomenon of treatment-resistant depression (TRD), described as the occurrence of an inadequate response after an adequate treatment with antidepressant agents (in terms of dose, duration, and adherence), is very common in clinical practice. It has been broadly defined in the context of unipolar major depression, but alternative definitions for bipolar depression have also been suggested. In both cases, there is a remarkable lack of consensus amongst professionals concerning its operative definition. A relatively wide variety of treatment options for unipolar TRD are available, whilst the evidence is very scanty for bipolar TRD. TRD is associated to poor clinical, functional, and social outcomes. Several novel therapeutic options are currently being investigated as promising alternatives, targeting the neurotransmitter system outside of the standard monoamine hypothesis. Augmentation or combination with lithium or atypical antipsychotics appears as a valid option for both conditions, and the same occurs with electroconvulsive therapy. Other non-pharmacological strategies such as deep brain stimulation may be promising alternatives for the future. The use of cognitive behaviour therapy is recommended for unipolar TRD, but there is no evidence supporting its use in bipolar TRD.
引用
收藏
页码:512 / 530
页数:19
相关论文
共 218 条
[1]   Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review [J].
Adli, M ;
Baethge, C ;
Heinz, A ;
Langlitz, N ;
Bauer, M .
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 2005, 255 (06) :387-400
[2]  
Adli M, 2003, PHARMACOPSYCHIATRY, V36, pS222
[3]   Effectiveness and feasibility of a standardized stepwise drug treatment regimen algorithm for inpatients with depressive disorders:: Results of a 2-year observational algorithm study [J].
Adli, M ;
Berghöfer, A ;
Linden, M ;
Helmchen, H ;
Müller-Oerlinghausen, B ;
Mackert, A ;
Stamm, T ;
Bauer, M .
JOURNAL OF CLINICAL PSYCHIATRY, 2002, 63 (09) :782-790
[4]   Algorithms and collaborative-care systems for depression: Are they effective and why? A systematic review [J].
Adli, Mazda ;
Bauer, Michael ;
Rush, A. John .
BIOLOGICAL PSYCHIATRY, 2006, 59 (11) :1029-1038
[5]   Serious life events among resistant and non-resistant MDD patients [J].
Amital, D. ;
Fostick, L. ;
Silberman, A. ;
Beckman, M. ;
Spivak, B. .
JOURNAL OF AFFECTIVE DISORDERS, 2008, 110 (03) :260-264
[6]  
Amsterdam J D, 1997, Depress Anxiety, V5, P84, DOI 10.1002/(SICI)1520-6394(1997)5:2<84::AID-DA4>3.3.CO
[7]  
2-N
[8]  
[Anonymous], J CLIN PSYCHIAT
[9]   Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors:: Results from a placebo-controlled, randomized, double-blind, placebo wash-in study [J].
Appelberg, BG ;
Syvälahti, EK ;
Koskinen, TE ;
Mehtonen, OP ;
Muhonen, TT ;
Naukkarinen, HH .
JOURNAL OF CLINICAL PSYCHIATRY, 2001, 62 (06) :448-452
[10]   Triiodothyronine augmentation in the treatment of refractory depression - A meta-analysis [J].
Aronson, R ;
Offman, HJ ;
Joffe, RT ;
Naylor, CD .
ARCHIVES OF GENERAL PSYCHIATRY, 1996, 53 (09) :842-848